The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 15, 2027

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Osimertinib

Osimertinib, 80mg, po, qd.

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER

NCT06477055 - The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter